TrialAntimicrobial agents and chemotherapy2018

Phase 1 Study To Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Multiple Oral Doses of DS-2969b, a Novel GyrB Inhibitor, in Healthy Subjects.

Alexander G Vandell et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.